

Remarks

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Applicants have amended the priority information on the face page of the Sequence Listing in order to reflect the current priority claim as amended at page 1 of the specification in the Amendment filed on August 15, 2003.

The current specification has been amended to insert the Substitute Sequence Listing, submitted herewith, which now reflects this correct priority claim. In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above-captioned application are the same. In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.


These changes are believed to introduce no new matter, and their entry is respectfully requested. Consideration of this Amendment and reconsideration of this application are respectfully requested.

Conclusion

Prompt and favorable consideration of this Amendment is respectfully requested. Applicants believe the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Peter A. Jackman
Attorney for Applicants
Registration No. 45,986

Date: Jan 20, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600